BiotecHeart will highlight product development progress
* pipelines/life-lines and research & development efforts
* product presentations that involve clinical development progress
* product presentations that are presented at key meetings/conferences
Thank you visiting www.biotecheart.com
this has been the “Biotech Decade” 2010-2019.
this year has been the “Biotech Year”.
Based on the current political environment it has been a spectacular year for the healthcare sector, and for many biotech companies.
There is no impossible.
2019, has been a breakthrough year for all who need medicine.
many clinical tests involving combinations of successful medicines.
many approvals this year in China for successful medicines.
Our differentiated approach to drug discovery and development has allowed us to create a broad portfolio of fully-owned product candidates with the potential for development in a wide range of psychiatric, neurological and related central nervous system (CNS) disorders.
. We have established a portfolio of programs by selecting disease targets based on a number of criteria, including unmet medical need, technical feasibility, advantages of CRISPR/Cas9 relative to other approaches and time required to advance the product candidate into and through clinical trials.
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for six Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
We’re building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology, nephrology, neurology, metabolics, and cardiology. We continue to evolve into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives.
Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.
Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
We are committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. We focus on our R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Disease. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority.
Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 90 clinical and pre-clinical projects, with the potential to deliver up to 15 new medicines by 2025, we continue our track record of long-term innovation-led performance.
AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates being developed for various oncology indications.
Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.
Alnylam is leading the translation of RNAi (RNA interference) into a whole new class of innovative medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases. .
Our product pipeline expands on our founding strategy to improve diagnostic accuracy by answering clinical questions in our indications further across the clinical care continuum, including early detection and informing treatment decisions. We also continue to evaluate intellectual property and corporate acquisitions that we believe answer clinically meaningful questions and enable better patient outcomes. We believe the global market opportunity for our products is over $30 billion annually.
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)
Dec. 10, 2019 2:42 PM ET | About: Roche Holding AG (RHHBY)
Interested in Lilly clinical trials? Learn more at LillyTrialGuide.com
A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.
Dec. 11, 2019 8:53 AM ET | About: AstraZeneca PLC (AZN)
Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
Dec 05, 2019
Novartis R&D Day London, UK December 5, 2019
Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.
(Select pipeline highlights as of January 2019)
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 10/15/19
We’re focused on developing transformative medicines for people with serious and life-threatening diseases.
We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.
The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
The Exelixis pipeline includes our lead compounds, cabozantinib and cobimetinib, as well as other programs that are the subject of partnerships and collaborations with several biopharmaceutical companies. An additional wholly owned compound, XL888, is the subject of ongoing clinical research through our Investigator-Sponsored Trial program. Safety and efficacy for these compounds in the unapproved uses or indications described below have not yet been established.
Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry.
We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates and three marketed products in China.
We are a community of scientists and creative innovators working to build a safer, healthier planet, and a more promising future.
Our unique expertise is in the design and engineering of astonishing living systems, from T-cells that battle cancer to non-browning apples. Across our diverse portfolio of projects we apply a common philosophy: bring together the greatest minds in synthetic biology and empower them to solve big problems.
We’re developing solutions through intrexon Health and intrexon Bioengineering. intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency.
Our strategy is to retain and develop product candidates ourselves in certain therapeutic areas that meet key criteria including having breakthrough potential for unmet needs; where development and commercialization are financially and operationally feasible; and where we see synergies across our product candidates and therapeutic approaches.
We are focusing our proprietary pipeline on research and development of product candidates for inherited metabolic diseases, central nervous system diseases, and immunology.
Collaboration is critical to maximizing the value of our platform technology and has brought important funding and expertise to our research. We will continue to collaborate, especially in therapeutic areas that are highly competitive or that require special disease area expertise or resources.
We are passionate about translating patients' unmet medical needs into novel ideas for therapeutic solutions. As a global provider of advanced treatments for diabetes and other serious chronic diseases, our goal is always to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
Jan 14, 2019, 07:44am Bernard Munos Contributor
I study pharmaceutical innovation, what causes it and how to get more of it. Several of my papers, published in Nature and Science, have helped stimulate a rethinking of the industry business model. In 2012, the popular newsletter FiercePharma named me one of the 25 most influential people in biopharma. In 2013, I became a Senior Fellow at FasterCures (a center of the Milken Institute). Besides doing research, I spend a lot of time helping organizations – big, small, public, private, US and non-US – become better innovators. I learned my trade in the 30 years I spent in the industry at Eli Lilly. Before that, I trained as an animal scientist in France and earned additional degrees in business and economics from Stanford and UC-Davis. I serve on various boards and advisory bodies, including at NCATS, the Institute of Medicine, Glenmark Pharmaceuticals, think tanks and foundations.